FEMY

FEMASYS INC. - 10-Q Summary (Q1 2026)

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026. Femasys Inc. is a biomedical innovator focused on women's health, specifically fertility (FemaSeed) and permanent birth control (FemBloc). The company is a non-accelerated filer, smaller reporting company, and emerging growth company. As of March 31, 2026, the company had $5.39 million in cash and cash equivalents.

Key Financial Metrics

Margins: Gross margin was approximately 62.6% ($266,283 / $424,889). The company reported a net income of $846,100, driven primarily by non-cash gains rather than operational profitability.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 24.5% to $424,889, primarily due to increased sales of the FemVue diagnostic product.
• Profitability Shift: The company reported a net income of $846,100 compared to a net loss of $5.9 million in Q1 2025. This reversal was almost entirely due to a $5.2 million non-cash gain from the change in fair value of derivative liabilities (Conversion Option and Warrants liabilities), offsetting an operating loss of $4.2 million.
• Expense Reduction: Total operating expenses decreased 21.0% to $4.49 million. Research and Development (R&D) expenses dropped significantly by 55.9% to $1.31 million, reflecting the transition of development products into inventory. Conversely, Sales and Marketing expenses increased 44.8% to $1.32 million.
• Liquidity: Cash and cash equivalents decreased by $3.88 million during the quarter, despite the reported net income, due to the non-cash nature of the income and continued negative operating cash flow.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year from the issuance of the financial statements. Current cash and anticipated revenues are expected to fund operations only into the third quarter of 2026.
• Financing Needs: The company requires additional financing to fund the U.S. clinical development of FemBloc and commercialization of FemaSeed. Failure to secure funding could force the termination of operations.
• Nasdaq Compliance: The company received a deficiency notice regarding the Minimum Bid Price Requirement (stock price below $1.00). Shareholders approved a reverse stock split (1-for-2 to 1-for-25) in April 2026 to regain compliance. Failure to comply by July 13, 2026, could result in delisting.
• Unusual Items: The net income for the quarter is not indicative of core operational performance. It is heavily influenced by the revaluation of derivative liabilities associated with the November 2025 convertible notes and warrants. In March 2026, the company modified these instruments, issuing new Series D-1 Warrants.
• Outlook: The company expects to incur additional losses and negative operating cash flows for the foreseeable future as it advances the FemBloc pivotal clinical trial (FINALE) and expands commercialization.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing agreements beyond the existing "at-the-market" facility and AMPA.
• Derivative Liability Volatility: Assess the sensitivity of future earnings to changes in the company's stock price, which drives the fair value of the significant warrant and conversion option liabilities.
• Nasdaq Compliance: Monitor the execution of the approved reverse stock split and the subsequent stock price to ensure compliance with the $1.00 minimum bid price requirement by July 13, 2026.
• Operational Cash Flow: Distinguish between the reported net income and the actual cash burn rate (negative $4.14 million in Q1) to understand true liquidity needs.
• Product Milestones: Track enrollment progress in the FemBloc FINALE pivotal trial and the commercial uptake of FemaSeed Complete, as these are critical for future revenue generation.